Changing Faces: Pharma and biotech hires, October 2026

R&D
Female HCP being recruited

October was a busy month for personnel changes, with a handful rising to the level of our daily news coverage and quite a few more worth noting in our monthly round-up.

Read on for the full rundown.

Bayer promotes internal leader to chief medical officer. Bayer looked internally for its new chief medical officer, appointing Dr Christoph Koenen to the role alongside his existing position as head of clinical development and operations for the pharmaceutical division. Koenen replaced Dr Mike Devoy, who left Bayer earlier in the year. Koenen, who joined Bayer in 2022, brings more than 25 years of pharmaceutical experience, including leadership positions at Bristol Myers Squibb, Novo Nordisk, Boehringer Ingelheim, and GSK. Read our full coverage here.

Saunders out at Bausch + Lomb. Eye care company Bausch + Lomb announced the departure of chief executive Brent Saunders, whose second stint leading the company came to an immediate end by mutual agreement with the board. Saunders, who returned as CEO in 2023 as Bausch Health worked toward making Bausch + Lomb an independent public company, oversaw a turnaround strategy focused on increasing investment in ophthalmic pharmaceuticals alongside the group's established contact lens and vision care businesses. Taking over on an interim basis is Thomas Appio, chairman of Bausch + Lomb and chief executive of parent company Bausch Health. Full story.

CSL, ViiV add new top leaders. Australian biopharma group CSL selected Deborah Waterhouse as its new chief executive starting next year. Waterhouse will join from ViiV Healthcare, where she has served as CEO since 2017 and also held the position of president of GSK Global Health. With more than 25 years of experience in global specialty pharmaceuticals, she previously spent two decades at GSK, including leadership roles across vaccines, primary care, and regional operations in Australia and New Zealand.

She succeeds interim chief executive Gordon Naylor, who has led the company since the departure of Paul McKenzie.

Following Waterhouse’s move to CSL, ViiV Healthcare announced that Lynn Baxter would take over her responsibilities. Baxter, who had been serving as president of GSK Europe, was appointed to lead both ViiV Healthcare and GSK Global Health.

Sibylla Biotech expands leadership team. Milan-based biotech Sibylla Biotech, which focuses on transforming drug discovery by targeting protein folding intermediates, strengthened its executive ranks with three key appointments.

  • The company named Dr Usman Azam as CEO. Before taking the role, Dr Azam led Novartis’ Cell and Gene Therapies Unit, where he helped deliver and launch the world’s first FDA-approved CAR-T therapy for haematologic cancers. He succeeds Lidia Pieri, who moves into the position of chief operating officer.
  • Alongside the CEO appointment, Gianluca Fuggetta joined as chief financial officer. Prior to joining Sibylla, Fuggetta served as senior vice president of finance and principal financial officer at Gain Therapeutics, a Nasdaq-listed clinical-stage biotechnology company.
  • The company also promoted Elena Ardini to chief scientific officer. Ardini brings more than 25 years of oncology research and development experience to the role and previously served as Sibylla’s vice president of research and development.

AL-S Pharma appoints new CEO. Swiss clinical-stage biotech AL-S Pharma, which is developing AP-101 for the treatment of amyotrophic lateral sclerosis, appointed Harry Welten as CEO.

Welten arrives with more than 15 years of board-level experience spanning life sciences, medtech, and AI diagnostics companies in Europe and the United States. He has served on 14 boards, seven of them as chairman, and previously helped guide Biognosys, Aidence, and Proteomedix through sales or mergers with Nasdaq-listed companies.

Spica Therapeutics names Jeff Abbey chief executive. Brussels-based biotech Spica Therapeutics, whose Macrophage Fingerprinting Platform underpins its work, selected Jeff Abbey as CEO. Abbey most recently led RNatives, an RNA-based gene-regulating therapeutics company, as chief executive before transitioning to chairman of the board. Earlier in his career, he served as chief operating officer and chief business officer at ImmunOs Therapeutics.

Orbis recruits experienced biotech leader. Orbis Medicines, a biotech focused on oral macrocycle drug discovery, appointed Joanne Smith-Farrell as CEO. Before joining the company, Smith-Farrell played a key role in building platform-focused organisations into multi-programme, clinical-stage companies during leadership positions at Be Biopharma and bluebird bio.

Two research non-profit hires. The Wistar Institute, a United States independent non-profit institution devoted to foundational biomedical research and training, appointed Dr Ronny Drapkin as president and CEO. Drapkin is a leading ovarian cancer researcher from the University of Pennsylvania. Across the pond, UK cancer charity Cancer Research UK named Mariam Jamal-Hanjani as chief clinician. Jamal-Hanjani is a clinician scientist, thoracic medical oncologist, and Professor of Cancer Genomics and Metastasis at the University College London Cancer Institute.

Sensorion strengthens executive team with two hires. Clinical-stage hearing-loss specialist Sensorion made two senior leadership appointments as it continues to work on therapies designed to restore, treat, and prevent hearing loss disorders. The company named Louis J Arcudi III chief financial officer. Arcudi most recently served as CFO of Amolyt Pharma, a French clinical-stage company focused on rare endocrine diseases. Sensorion also appointed Dr Peter Weber as chief medical officer. Weber brings experience gained at Decibel Therapeutics, Regeneron, and Cochlear, and most recently served as chief medical officer at Auregen BioTherapeutics.

Frontier Medicines adds trio of development leaders. Clinical-stage precision medicines company Frontier Medicines Corporation, which is advancing therapies for genetically defined patient populations in oncology and immunology, expanded its leadership team with three appointments:

  • Dr Aaron Weitzman joined as chief medical officer, bringing more than 25 years of pharmaceutical and biotechnology drug development experience, including 15 years in senior clinical leadership roles at major pharmaceutical companies.
  • Mike Preigh was named chief technical operations officer after most recently serving as chief technical officer at Day One Biopharmaceuticals.
  • Joelle Lufkin joined as senior vice president of clinical development and strategy. Before joining Frontier, she spent more than seven years leading JLK Clinical Consulting, advising emerging biotech companies from candidate nomination through IND-enabling activities and first-in-human studies.

Four biotechs add new CMOs. A number of biotechs this month hired chief medical officers to lead their scientific endeavours.

  • Norwegian radiopharmaceutical company Oncoinvent named Dr Zuzana Jiráková Trnková chief medical officer. Before joining the company, Trnková held senior leadership positions at Bayer, BioNTech, and Highlight Therapeutics. Most recently, she served as chief medical officer at Highlight, where she oversaw clinical development, regulatory and medical strategy, and patient safety.
  • UK-based biotechnology company RQ Bio, which develops long-acting monoclonal antibodies against seasonal influenza, appointed Gavin Koh as chief medical officer. Koh previously held senior positions at AstraZeneca and GSK, leading programmes from discovery through registration and launch, including work on Evusheld during the COVID-19 pandemic.
  • Seraxis, which develops stem cell-derived pancreatic islets using cGMP manufacturing processes, selected Dr Patricia Beaston as chief medical officer. Prior to joining the company, Beaston worked across multiple FDA centres, including CDER, CDRH, and CBER. Her review responsibilities included islet cell transplantation, immune modulation in type 1 diabetes, and cell and gene therapies.
  • Swedish company Simris Group, focused on innovative antibody-drug conjugates based on differentiated payload technologies, appointed Dr András Strassz as chief medical officer. Strassz joined from Heidelberg Pharma, where he had served as chief medical officer and built the company’s clinical development function.

Two pharmas add scientific leadership. Biopharmaceutical company Adial Pharmaceutical, which develops treatments for serious inflammatory diseases, named Dr David Rubenstein, formerly CSO at Dermavant Sciences as chief scientific officer. Meanwhile, Swiss biotech Numab Therapeutics, developer of multispecific antibody-based immunotherapies for inflammatory diseases and cancer, appointed Dr Rajesh Chopra as chief scientific officer. Before joining Numab, Chopra served as chief scientific officer at Prologue Medicines and was also a venture partner at Apple Tree Partners.

Lift Therapeutics hires clinical development chief. London-based preclinical biotech Lift Therapeutics, formerly known as LifT BioSciences, appointed Dr Eva Ehrnrooth as executive head of clinical development. A board-certified oncologist, Ehrnrooth previously served as chief medical officer at IO Biotech.

Experienced CFO joins French biotech. French biotechnology company Enodia Therapeutics, which develops small-molecule therapies designed to degrade disease-driving proteins at the point of synthesis, appointed Henrik Torp Nielsen as chief financial officer. Most recently, Nielsen helped secure €132 million in financing at Azafaros AG and previously spent more than 15 years in senior finance leadership positions at Novartis.

ProMIS appoints CCO with big pharma bona fides. Clinical-stage biotechnology company ProMIS Neurosciences, which focuses on neurodegenerative diseases caused by toxic misfolded proteins, appointed Ivana Rubino as chief commercial officer. Rubino brings more than 15 years of global neuroscience leadership experience from Biogen and Roche, most recently serving as vice president and global head of Alzheimer's disease and multiple sclerosis medical at Biogen.

ViroMissile adds two senior advisers. Cancer immunotherapy company ViroMissile, which is developing a systemically delivered oncolytic virus platform, expanded its advisory team with two appointments. Dr Diane Simeone joined as clinical advisor. A pancreatic surgeon and cancer researcher with 27 consecutive years of NIH funding, Simeone pioneered adaptive platform trials in pancreatic cancer, co-chaired the AACI Accelerating Clinical Trials Steering Committee, and leads the 65-centre PRECEDE Consortium focused on early pancreatic cancer detection. The company also appointed Matt Mulvey as strategic advisor. Mulvey co-developed the HSV backbone licensed for T-VEC, the first FDA-approved oncolytic virus, and the same platform technology underlies Replimune's O-Vec.

InflaRx appoints clinical development leader. German biopharmaceutical company InflaRx, a pioneer of anti-inflammatory therapeutics, named Dr Gabriela Alperovich senior vice president and global head of clinical development. Alperovich is a physician-scientist and nephrologist with more than two decades of pharmaceutical industry experience, having held leadership positions at CSL Vifor, AbbVie, and Bristol Myers Squibb.

Formation Bio recruits translational sciences head. AI-native pharma company Formation Bio, which has built technology and AI systems to accelerate drug development and clinical trials, appointed Anirvan Ghosh as senior vice president and head of R&D translational sciences. Ghosh boasts decades of experience spanning senior R&D positions at Roche and Biogen, as well as acting as founding chief scientific officer of E-Scape Bio and chief executive officer of Unity Biotechnology.

That’s it for our October life sciences hires, but stay tuned for our other hires round-ups and remember, you can send your own hires to editorial@pharmaphorum.com for inclusion in this column.